New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

Insurance companies generally cover Ozempic and Wegovy when it is prescribed for Type 2 diabetes. However, when the drugs are ...

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...

Wealth host Brad Smith discusses some of Wednesday's trending stocks. Novo Nordisk (NVO) stock is sinking after European drugmaker Roche (ROG.SW) reached a deal with Zealand Pharma (ZEAL.CO) to ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

G LP-1 drugs containing semaglutide (the active ingredient in Ozempic and Wegovy) have exploded in popularity for their ...